To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Russia: Ukraine
Tuesday 15th July 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment his Department has made of the potential implications for its policies of reports of the alleged use of Ukrainian children by Russian forces in attacks on Ukrainian military assets.

Answered by Stephen Doughty - Minister of State (Foreign, Commonwealth and Development Office)

In Russia and the temporarily occupied territories of Ukraine, Russian authorities have introduced "military-patriotic" training in schools and in youth groups and expose Ukrainian children to military propaganda, urging enlistment in the Russian armed forces. This is a despicable and systematic attempt to erase Ukrainian identity, and with it, Ukraine's future. We are also aware of reports that Russia is recruiting Ukrainian teenagers and young adults to carry out espionage and sabotage in Ukraine. We are determined to hold those responsible for the militarisation of Ukrainian children to account. In November 2024, we announced a third round of sanctions targeting those attempting to forcibly deport and indoctrinate Ukrainian children, including through the use of "military-patriotic" education.


Written Question
Ukraine: Children
Monday 12th May 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what discussions he has had with his US counterparts on funding for initiatives tracking stolen Ukrainian children in temporarily occupied territories.

Answered by Stephen Doughty - Minister of State (Foreign, Commonwealth and Development Office)

The UK works closely with our allies, including the US, on this issue. The UK has funded 'Save Ukraine', a non-governmental organisation which helps to return Ukrainian children, and 'Bring Kids Back UA' through The Partnership Fund for a Resilient Ukraine. In March, I met representatives from both organisations, alongside Ukrainian Deputy Foreign Minister Mariana Betsa and senior officials from the Ministry of Justice, to discuss child deportation. The UK has issued three sanctions packages targeting those attempting to forcibly deport and indoctrinate Ukrainian children. We are also a member of the International Coalition for the Return of Ukrainian Children.


Written Question
Living Wage and Minimum Wage: Wales
Wednesday 30th April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Wales Office:

To ask the Secretary of State for Wales, what assessment she has made of the potential impact of changes in the level of the national minimum wage and living wage on people in Wales.

Answered by Jo Stevens - Secretary of State for Wales

Up to 160,000 workers in Wales have just received a pay rise as the increases in the National Living Wage and National Minimum Wage take effect.

Full-time workers on the National Living Wage will see a real-terms pay increase of £1,400 per year, whilst 18-to-20 year olds will get a record boost of £2,500 each year, helping to provide families with better financial stability, improved living standards and kickstarting growth.


Written Question
Cheetahs: Hunting
Monday 28th April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, whether his Department plans to ban the import of cheetah trophies.

Answered by Mary Creagh - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)

The Government committed to a ban on the import of hunting trophies of endangered animals in its manifesto and will deliver on this. Defra is currently engaging with a range of stakeholders in order to decide on the most effective approach.


Written Question
Cheetahs: Hunting
Monday 28th April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, how many permits were issued for cheetah trophies in the 2024-25 financial year.

Answered by Mary Creagh - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)

The Animal and Plant Health Agency (APHA) is responsible for releasing data on hunting trophy import permits. APHA has not yet released its data on permits issued for hunting trophies in the 2024-25 financial year. This information will be published on the CITES trade database later this year. Available here.


Written Question
Health Services: Immunosuppression
Wednesday 2nd April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support immunocompromised people.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/12/specialist-immunology-adults-service-specification.pdf

The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf

Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.

Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:

https://www.sciencedirect.com/science/article/pii/S016344532500026X

NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.

The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.


The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:

https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk

No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.


Written Question
Immunosuppression: Departmental Coordination
Wednesday 2nd April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of establishing a cross-departmental taskforce for for immunocompromised patients.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/12/specialist-immunology-adults-service-specification.pdf

The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf

Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.

Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:

https://www.sciencedirect.com/science/article/pii/S016344532500026X

NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.

The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.


The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:

https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk

No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.


Written Question
Health Services: Immunosuppression
Wednesday 2nd April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when his Department last issued guidance for clinicians on treating immunocompromised patients in health settings.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/12/specialist-immunology-adults-service-specification.pdf

The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf

Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.

Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:

https://www.sciencedirect.com/science/article/pii/S016344532500026X

NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.

The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.


The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:

https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk

No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.


Written Question
Immunosuppression
Wednesday 2nd April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people in the United Kingdom are clinically defined as immunocompromised.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/12/specialist-immunology-adults-service-specification.pdf

The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf

Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.

Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:

https://www.sciencedirect.com/science/article/pii/S016344532500026X

NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.

The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.


The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:

https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk

No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.


Written Question
Health Services: Immunosuppression
Wednesday 2nd April 2025

Asked by: Johanna Baxter (Labour - Paisley and Renfrewshire South)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when did his Department last issue guidance to patients that are immunocompromised.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/12/specialist-immunology-adults-service-specification.pdf

The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2021/12/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf

Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.

Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:

https://www.sciencedirect.com/science/article/pii/S016344532500026X

NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.

The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.


The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:

https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk

No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.